Antipsychotic-induced weight gain and therapeutic response: A differential association

Pál Czobor, Jan Volavka, Brian Sheitman, Jean Pierre Lindenmayer, Leslie Citrome, Joseph Patrick McEvoy, Thomas B. Cooper, Miranda Chakos, Jeffrey A. Lieberman

Research output: Contribution to journalArticle

160 Citations (Scopus)

Abstract

This study investigated the association between antipsychotic-induced weight gain and therapeutic response to haloperidol and three commonly used atypical neuroleptic medications in schizophrenia and schizoaffective disorder. The subjects were 151 patients enrolled in a double-blind experiment with a duration of 14 weeks comparing the therapeutic efficacy of haloperidol (n = 36), clozapine (n = 38), olanzapine (n = 38), and risperidone (n = 39). Absolute and relative (%) gain in body weight and body mass index (BMI) was determined for the entire duration of the double-blind treatment period; therapeutic response was assessed by the total score and the individual subscales of the Positive and Negative Symptom Scale. Compared with the pretreatment baseline, results indicated that for olanzapine and clozapine, therapeutic response was closely related to an absolute and relative gain in weight and to a gain in BMI. No association between weight gain and therapeutic response was found for risperidone and haloperidol. These findings suggest that patients who are likely to have the maximal benefits of olanzapine or clozapine treatment for symptom alleviation are at the highest risk of a clinically significant increase in weight gain.

Original languageEnglish (US)
Pages (from-to)244-251
Number of pages8
JournalJournal of Clinical Psychopharmacology
Volume22
Issue number3
DOIs
StatePublished - Jun 3 2002
Externally publishedYes

Fingerprint

Antipsychotic Agents
Weight Gain
olanzapine
Clozapine
Haloperidol
Risperidone
Therapeutics
Body Mass Index
Psychotic Disorders
Schizophrenia
Body Weight

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Antipsychotic-induced weight gain and therapeutic response : A differential association. / Czobor, Pál; Volavka, Jan; Sheitman, Brian; Lindenmayer, Jean Pierre; Citrome, Leslie; McEvoy, Joseph Patrick; Cooper, Thomas B.; Chakos, Miranda; Lieberman, Jeffrey A.

In: Journal of Clinical Psychopharmacology, Vol. 22, No. 3, 03.06.2002, p. 244-251.

Research output: Contribution to journalArticle

Czobor, P, Volavka, J, Sheitman, B, Lindenmayer, JP, Citrome, L, McEvoy, JP, Cooper, TB, Chakos, M & Lieberman, JA 2002, 'Antipsychotic-induced weight gain and therapeutic response: A differential association', Journal of Clinical Psychopharmacology, vol. 22, no. 3, pp. 244-251. https://doi.org/10.1097/00004714-200206000-00003
Czobor, Pál ; Volavka, Jan ; Sheitman, Brian ; Lindenmayer, Jean Pierre ; Citrome, Leslie ; McEvoy, Joseph Patrick ; Cooper, Thomas B. ; Chakos, Miranda ; Lieberman, Jeffrey A. / Antipsychotic-induced weight gain and therapeutic response : A differential association. In: Journal of Clinical Psychopharmacology. 2002 ; Vol. 22, No. 3. pp. 244-251.
@article{a0473c7d4c694b23aecfe17c827adea6,
title = "Antipsychotic-induced weight gain and therapeutic response: A differential association",
abstract = "This study investigated the association between antipsychotic-induced weight gain and therapeutic response to haloperidol and three commonly used atypical neuroleptic medications in schizophrenia and schizoaffective disorder. The subjects were 151 patients enrolled in a double-blind experiment with a duration of 14 weeks comparing the therapeutic efficacy of haloperidol (n = 36), clozapine (n = 38), olanzapine (n = 38), and risperidone (n = 39). Absolute and relative ({\%}) gain in body weight and body mass index (BMI) was determined for the entire duration of the double-blind treatment period; therapeutic response was assessed by the total score and the individual subscales of the Positive and Negative Symptom Scale. Compared with the pretreatment baseline, results indicated that for olanzapine and clozapine, therapeutic response was closely related to an absolute and relative gain in weight and to a gain in BMI. No association between weight gain and therapeutic response was found for risperidone and haloperidol. These findings suggest that patients who are likely to have the maximal benefits of olanzapine or clozapine treatment for symptom alleviation are at the highest risk of a clinically significant increase in weight gain.",
author = "P{\'a}l Czobor and Jan Volavka and Brian Sheitman and Lindenmayer, {Jean Pierre} and Leslie Citrome and McEvoy, {Joseph Patrick} and Cooper, {Thomas B.} and Miranda Chakos and Lieberman, {Jeffrey A.}",
year = "2002",
month = "6",
day = "3",
doi = "10.1097/00004714-200206000-00003",
language = "English (US)",
volume = "22",
pages = "244--251",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Antipsychotic-induced weight gain and therapeutic response

T2 - A differential association

AU - Czobor, Pál

AU - Volavka, Jan

AU - Sheitman, Brian

AU - Lindenmayer, Jean Pierre

AU - Citrome, Leslie

AU - McEvoy, Joseph Patrick

AU - Cooper, Thomas B.

AU - Chakos, Miranda

AU - Lieberman, Jeffrey A.

PY - 2002/6/3

Y1 - 2002/6/3

N2 - This study investigated the association between antipsychotic-induced weight gain and therapeutic response to haloperidol and three commonly used atypical neuroleptic medications in schizophrenia and schizoaffective disorder. The subjects were 151 patients enrolled in a double-blind experiment with a duration of 14 weeks comparing the therapeutic efficacy of haloperidol (n = 36), clozapine (n = 38), olanzapine (n = 38), and risperidone (n = 39). Absolute and relative (%) gain in body weight and body mass index (BMI) was determined for the entire duration of the double-blind treatment period; therapeutic response was assessed by the total score and the individual subscales of the Positive and Negative Symptom Scale. Compared with the pretreatment baseline, results indicated that for olanzapine and clozapine, therapeutic response was closely related to an absolute and relative gain in weight and to a gain in BMI. No association between weight gain and therapeutic response was found for risperidone and haloperidol. These findings suggest that patients who are likely to have the maximal benefits of olanzapine or clozapine treatment for symptom alleviation are at the highest risk of a clinically significant increase in weight gain.

AB - This study investigated the association between antipsychotic-induced weight gain and therapeutic response to haloperidol and three commonly used atypical neuroleptic medications in schizophrenia and schizoaffective disorder. The subjects were 151 patients enrolled in a double-blind experiment with a duration of 14 weeks comparing the therapeutic efficacy of haloperidol (n = 36), clozapine (n = 38), olanzapine (n = 38), and risperidone (n = 39). Absolute and relative (%) gain in body weight and body mass index (BMI) was determined for the entire duration of the double-blind treatment period; therapeutic response was assessed by the total score and the individual subscales of the Positive and Negative Symptom Scale. Compared with the pretreatment baseline, results indicated that for olanzapine and clozapine, therapeutic response was closely related to an absolute and relative gain in weight and to a gain in BMI. No association between weight gain and therapeutic response was found for risperidone and haloperidol. These findings suggest that patients who are likely to have the maximal benefits of olanzapine or clozapine treatment for symptom alleviation are at the highest risk of a clinically significant increase in weight gain.

UR - http://www.scopus.com/inward/record.url?scp=0036115924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036115924&partnerID=8YFLogxK

U2 - 10.1097/00004714-200206000-00003

DO - 10.1097/00004714-200206000-00003

M3 - Article

C2 - 12006893

AN - SCOPUS:0036115924

VL - 22

SP - 244

EP - 251

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 3

ER -